Anavex Life Sciences Corporation News - AVXL

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Expansion of Leadership Team

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex...

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May...

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:...

May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL

May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL PR Newswire NEW YORK...

sab63090 2 minutes ago

The $XBI is rebounding and looks pretty good, might help with the reversal and resumption in trend for $AVXL

👍️0

sab63090 7 minutes ago

What are the odds that the RSI hits 90 to reassert and confirm the upside momentum with price in sync with it or at least the historic level of 80?

👍️0

Investor2014 26 minutes ago

How very American - this drug advertisement will be briefly interrupted by the main programme.

Does anyone actually listen to all that advertising crap?

👍️ 1

plexrec 27 minutes ago

Just saw another ad pass as I write this--BFRO---Bullfrog Ai Holdings--drug discovery---another "smart" marketing move !!! We should learn !!!!

🤡 1

plexrec 32 minutes ago

hnbad---" does not have an approved drug"--of course I do---does not mean co.can't do a "Presentation" via TV advertising--no one (practically) has ever heard of Anavex---tell the world how close we are--are you happy with our SP ?? Advertising is a way to "tell the world"--some who are watching may want in !!!!!!

🤡 1

hnbadger1 49 minutes ago

Plex, you do realize the Anavex does not have an approved drug to advertise?

👍️ 1

plexrec 51 minutes ago

"Advertising" on CNBC !!! On recent days I've seen "real" ads on TV from young Biotech companies marketing their co. and it's products ! Really not a bad idea--a way to "get the word out"--telling the world "who they are and what they have"--in fact just now an ad from BIOVIE-- BIVI just passed on the tv screen--talked about their PD drug. Someone should suggest same to our IR. A good way to tell folks about ANAVEX---tell the world !!!!!!! ADVERTISING WORKS !!!! Herr Missling--give it a try---enough of "under the radar"-that hasn't worked !

👍️ 1 😁 1 🤡 1

ExtremelyBullishZig 2 hours ago

What is the title? The short is the proper play here.

👍️0

Investor2014 3 hours ago

Just the 2nd entry on the list, which is a straight forward read and not really indicative of any new news, but we can hope…

👍️ 1

sab63090 4 hours ago

Holy smokes every other word was not understood by the "dummy in the class"....me!

👍️0

sab63090 4 hours ago

Thanks for your explanations and clarifications....now between a short term double bottom and double top, good that there is a positive divergence going on with the price drop and the RSI not going lower....good luck

👍️0

sab63090 4 hours ago

Yes, and we are in agreement with that price level....oh yeah, it's the magical 200 day sma...on the daily....the weekly definitely broke the 50 week and the price stopped dead at the prior highs (so far)....I'm remaining positive.

👍️0

sab63090 4 hours ago

The problem with the Short Interest Report that needs to be addressed is that it is OLD NEWS and ignores the fact that the last 10 days of wonderful price action is not seen.

Traders, mm's and hedge funds know this and hardly ever stay with positions for long periods of time.

Just based on momentum I would anticipate more upside into Friday....

👍️ 1

sab63090 4 hours ago

Right you are Tom! As I mentioned, the "minimum" count has been achieved and the way I review the counts is using wave 3 and working backwards to see if the progression of the waves conforms well. Wave 3's are associated with excitement and sustained moves (up or down) and sometimes don't follow through as what happened to Prechter's Big "Three of Three" to a larger sequence failed miserably in March 1989, when the market turned back up and did not look back.

Hope my memory served me well on this.

I'm using the drop to $6.47 as Wave 4 as support and the push to right under $7 as Wave 5. notice that $6.47 is also the 200 Day SMA on the daily; the best news is that the WEEKLY took out the one year downtrend (50 week) and seems to have more to go based on prior tops in the RSI @ around 78 to 80...

I need to point out that on the DAILY that we now have a negative divergence in the RSI in that the price moved to a new swing high but was not confirmed with the RSI. That might be because of the overall weakness in the market...so that is just a short term cautionary..🤔

Yesterday's action in $AVXL was favorable especially against a big drop especially in the NASDAQ and other indexes....hardly ever see a drop that big (minus 3.60%).... !!!!

🏁 1 👍️ 2

Investor2014 5 hours ago

Nothing Anavex I can find in that program, but this: blarcamesine (Anavex 2-73) / Anavex - LARVOL DELTA indicates an embargoed behind AAIC login presentation.
Blarcamesine in Early Alzheimer Disease Phase 2b/3 Randomized Clinical Trial (AAIC 2024) - "In this phase 2b/3 randomized clinical trial, we found that among participants with early AD, blarcamesine significantly slowed clinical progression on prespecified primary outcome global and cognitive measures at 48 weeks in the ITT population. These results suggest that blarcamesine may be an effective, safe, and novel scalable oral treatment for early AD."
Clicking on the link above, the title points to an AAIC login page.

👍️ 1

crescentmotor 7 hours ago

As amply demonstrated by the comments on his article, relying on Lane Simonian, a retired history professor, for advice on SAVA is akin to being dependent on kund on Investors Hub for advice concerning AVXL. Lane draws his conclusions about Simufilam's efficacy past one year of treatment based on his complete misunderstanding of the six month Simufilam withdrawal study where he doesn't understand that the "placebo" group (admittedly a confusing term used by SAVA) had already been on Simufilam for one year. As a result, the so-called "placebo" group's statistics were improved from the lingering positive carryover effects of prior Simufilam administration. Very few people understand that nuance in the trial results and SAVA indeed could have done a much better job reporting out the trial results. SAVA should not have named the withdrawal group "placebo" as it really wasn't (given the normal/usual structure of trials) and this caused a lot of confusion in interpreting the trial results. Lane repeatedly questions the MOA of Simufilam without acknowledging that several independent companies and distinguished scientists had conducted studies confirming the MOA. In completed open label trials (placebo controlled for the withdrawal phase), the bottom line is that 47 patients with mild Alzheimer's disease who received Simufilam treatment continuously for two years had no decline in ADAS-Cog scores as a group. 40 other patients who participated in the six month drug withdrawal study and did not receive Simufilam for six months and then were placed back on Simufilam suffered only a one point decline in ADAS-Cog. Two safety inspections by the DSMB have resulted in recommendations that SAVA's two ongoing Phase III trials should continue. Blinded interim safety analysis have shown that Simufilam is not associated with treatment-emergent ARIA. Simufilam is an oral drug and treatment does not require infusions or follow-on MRIs. Last patient visit in the first Phase III trial (RETHINK) is expected in October 2024 with top line data expected shortly thereafter.

Investor Presentations:

https://www.cassavasciences.com/company-presentations

👍️ 1

Rubyred77 8 hours ago

What’s the title?

👍️0

georgejjl 10 hours ago

The actual presentation trial is very very impressive.

If you disagree, then maybe you should short AVXL even more than you already have shorted AVXL.

GOD bless,

🆖 1 💩 1

Bourbon_on_my_cornflakes 10 hours ago

well said, really well said

👍️0

ExtremelyBullishZig 10 hours ago

In other words, the presentation title doesn't impress and actually will most likely not present anything new.

💩 1 🦨 1

georgejjl 12 hours ago

He is making a presentation directly about Anavex's blarcamesine Phase 2b/3 trial results.

Good luck and GOD bless,

🆖 1 💩 1

Kb1123 13 hours ago

What’s the headline of his presentation? Because he’s not talking specifically about Anavex

👍️0

bb8675309 14 hours ago

Cassava Sciences: Turning The Corner Into A Brick Wall - By Lane Simonian

https://seekingalpha.com/article/4706021-cassava-sciences-turning-the-corner-into-a-brick-wall?mailingid=36173368&messageid=must_reads&serial=36173368.924982&source=email_must_reads&utm_campaign=Must%2BReads%2B-%2BProduct%2Bteam%2Btest%2B-%2BNo%2Btest%2Bversion%2B2024-07-24&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads

👍️0

mauismart 15 hours ago

I think you pur in too much thought in this post. What kind of thought who knows

👍️ 2

poguemahone 15 hours ago

Here goes my technical analysis: the closing price of $6.48 represents the lower channel of the band that extended through to $6.73. $6.73 represents the resistance zone, as this price has been tested, retested, and retreated. Bollinger bands and stochastic modeling indicate the price could go higher, but it certainly could go lower as well. The key to watch for is if the color is green, the price is higher, which then means it could go lower or remain unchanged, as traders generally want to make money. Look for the stock to go up or down, but it might also remain unchanged if buyers lack conviction. It’s too hard to call right now, so I’ll get back to you tomorrow at 4:30 to let you know what already happened.

🎯 1 👍️ 2

frrol 15 hours ago

Why your "study group" is empty.

👍️0

boi568 15 hours ago

You might be better off counting the waves in the ocean.

👍️ 6

poguemahone 16 hours ago

Suggestion: Go to the beach and count the waves lapping the shoreline. This analysis is pure, unadulterated crap.

👍️0

123tom 16 hours ago

Looking at EW...
Like you said ,counting waves can be a little tricky. You can see 5 waves up, but also it could extend to 7 waves. I've even counted 9 waves in a finished pattern at times.
Sometimes it helps when I go back to the bottom and start over. I can clearly see the 1st upwave, from 3.25/3.40 bottom to finish peak around 4.50/4.60. As Wave 1
Wave 2 pulls back and holds support at 3.50/3.65/3.73.
Then we get the latest surging upwave that peaked at 6.80. This is the more difficult wave to analyze because depending on how you count it, could be a wave 3,4,and 5 finished.Or... it could be just one wave 3, you know ,like counting 1 of 5 of 3, 2 of 5 of 3, etc. The pullback around 6.40 is looking zig zaggy like a Wave 4.... so that's why I'm thinking the surge to 6.80 was only a Wave 3 , now sideways zig zag is wave 4, and we could anticipate wave 5 to target 7.60-8.40 area as a finished pattern.

🏁 1 👍️ 2

LakeshoreLeo1953 17 hours ago

I know it is the LATEST information
and in context is lowest in 6+ reports except
for the last

BUT….to think the increase correlates as you posited with today’s/recent SP is very much a stretch.
Any takers the next report (representative of today’s positioning) is fewer shorts?

“Why look for conspiracy when stupidity can explain so much.”
Goethe

Even the BMW should sound loud in the Chesapeake Tunnel/Bridge. Kittyhawk and home Friday.

What will Monday think of AAIC and AVXL?

🏁 1 👍️ 1 💩 2 🦨 2

bb8675309 17 hours ago

Shorty trying to keep a cap on the price maybe.🤔

🏁 1 👍️ 1

kund 17 hours ago

You mean Misleading finally found a needle in the haystack. Is it the right needle or another nothingburger?

💩 1 🦨 2

plexrec 17 hours ago

Piano player Pauline Stevens--video a bit dated yet so meaningful--why no followup coverage--???? https://www.heraldsun.com.au/news/national/steve-macfarlane-explains-the-alzheimers-worldfirst-drug-trial-at-caulfield-hospital/video/03fe27ae89bdce4912cabf865a99ed80

🏁 2 👍️ 2

georgejjl 18 hours ago

YES!!! I am expecting new--needle moving info from this presentation!!!

MRI brain volume (atrophy) etc.

Good luck and GOD bless,

🆖 1 🍼 1 👍️ 1 💥 1

mike_dotcom 18 hours ago

https://www.nasdaqtrader.com/Trader.aspx?id=ShortInterest

🏁 1 👍️ 1

plexrec 18 hours ago

"The oral session is scheduled for 4:30"--george--are you expecting-anything new--needle moving info from this Presentation ????

👍️0

RedShoulder 18 hours ago

Nasdaq 17,342.41 -654.94 (-3.64%)

AVXL held up pretty well considering the entire markets were deep in the red.

🏁 1 👍️ 3

longtermbeliever 18 hours ago

short shares are up and our SP is up as well humm.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

🆖 1 💩 1

investingdog 18 hours ago

Where do you get latest short interest? Nasdaq only shows 6/28/2024. Thanks.

👍️0

RedShoulder 18 hours ago

Short Report just out: 07/15/2024 18,440,980

07/15/2024 18,440,980 3.45 802,783 22.97
06/28/2024 17,825,737 (14.89) 1,692,163 10.53
06/14/2024 20,944,467 (4.00) 1,071,745 19.54
05/31/2024 21,816,277 (0.20) 1,033,741 21.10
05/15/2024 21,860,442 2.68 1,029,913 21.23

https://nasdaqtrader.com/Trader.aspx?id=ShortInterest

👍️ 2

bb8675309 18 hours ago

Right! It's only under valued by $75.00 per share or so. Lol..

🏁 1 👍️ 2

georgejjl 18 hours ago

The oral session is scheduled for 4:30 PM EDT on Sunday 28 July 2024.

The shorts have to cover on Friday 26 July 2024 if the need to cover before the AAIC presentation.

Good luck and GOD bless,

🆖 1 🍼 1 👍️ 2 💥 1

longtermbeliever 18 hours ago

super strong today.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

🆖 1 🍼 1 🏁 1 👍️ 3

sab63090 18 hours ago

Holding up here...1 minute chart

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=avxl&x=23&y=13&time=1&startdate=1%2F4%2F1999&enddate=4%2F12%2F2018&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=1&maval=55550&uf=8&lf=2&lf2=8&lf3=4&type=4&style=350&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11

👍️0

sab63090 19 hours ago

Looks like the Standoff at the OK Coral

I thought the volume would have been less, but this certainly shows that outside interests don't want to risk seeing $7 broken! With the NASDAQ down 3.50% and the short interest coming out after 4pm,

I think the stock itself has held up pretty darn well....still 40 minutes to go; I am flat footed right now.

🏁 1 👍️ 1

williamssc 19 hours ago

Blarcamesine's safety, efficacy and ease of use likely raises concerns for BP's mabs which has seen a sales drop. And then there's the EMA that's waiting on a better alternative... such as a safe effective oral pill that reduces brain shrinkage. hmm

🎯 4 🏁 1 👍️ 12 👏 2

WilliamMunny 19 hours ago

Which session/time is that, George?

👍️ 1

georgejjl 19 hours ago

This coming Sunday 28 July 2024 Dr. Marwan N Sabbagh, MD will be make an oral presentation at the 2024 AAIC Meeting concerning the results from the Phase 2b/3 Alzheimer's trial using blarcamesine.

That means that Friday 26 July 2026 will be the last time for the shorts to cover before the AAIC Meeting!!!

Good luck and GOD bless,

🆖 1 🍼 1 🏁 1 👍️ 7

georgejjl 19 hours ago

Expect the AVXL share price to close at or near the high of the day on increasing buying volume near the close of trading today.

Good luck and GOD bless,

🆖 1 💩 1 🤡 2

powerwalker 20 hours ago

Some hedge firms/MM must be worried about the growth side of Anavex's SP, such that, they brought Anshu2 back after 2+ months away (and probably from other assignments under another name(s)).

🏁 1 👍️ 8

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Anavex Life Sciences Corporation (AVXL)

Empower your portfolio: Real-time discussions and actionable trading ideas.

AVXL News

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Expansion of Leadership Team

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL

AVXL Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Anavex Life Sciences Corporation (AVXL) News

Anavex Life Sciences Corporation (AVXL)

Empower your portfolio: Real-time discussions and actionable trading ideas.

AVXL News

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences Announces Expansion of Leadership Team

Form 4 - Statement of changes in beneficial ownership of securities

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL

AVXL Discussion

Your Recent History

Company

Business

Popular

Get The App